Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson’s disease
- Naoto Kadoguchi†1,
- Shinji Okabe†1,
- Yukio Yamamura1,
- Misaki Shono1,
- Tatsuya Fukano1,
- Akie Tanabe1,
- Hironori Yokoyama1 and
- Jiro Kasahara1Email author
© Kadoguchi et al.; licensee BioMed Central Ltd. 2014
Received: 14 May 2014
Accepted: 19 June 2014
Published: 25 June 2014
Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), shows multiple pharmacological actions such as inhibiting presynaptic α2 noradrenaline receptor (NAR) and selectively activating 5-hydroxytriptamine (5-HT) 1A receptor (5-HT1AR). Mirtazapine was also reported to increase dopamine release in the cortical neurons with 5-HT dependent manner. To examine whether mirtazapine has a therapeutic potency in Parkinson’s disease (PD), we examined this compound in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice model of PD.
Male C57BL/6 mice were subjected to MPTP treatment to establish a PD model. Mirtazapine was administered once a day for 3 days after MPTP treatment. MPTP-induced motor dysfunction, assessed by beam-walking and rota-rod tests, was significantly improved by administration of mirtazapine. Biochemical examinations by high performance liquid chromatography and western blot analysis suggested mirtazapine facilitated utilization of dopamine by increasing turnover and protein expression of transporters, without affecting on neurodegenerative process by MPTP. These therapeutic effects of mirtazapine were reduced by administration of WAY100635, an inhibitor for 5HT1AR, or of clonidine, a selective agonist for α2-NAR, or of prazosin, an inhibitor for α1-NAR, respectively.
Our results showed mirtazapine had a therapeutic potency against PD in a mouse model. Because PD patients sometimes show depression together, it will be a useful drug for a future PD treatment.
Keywords1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Parkinson’s disease Mirtazapine Noradrenergic and specific serotonergic antidepressant (NaSSA) Serotonin (5-hydroxytryptamine, 5-HT) Dopamine
Parkinson’s disease (PD) is a progressive, age-related, neurodegenerative disorder characterized by bradykinesia, resting tremor and gait disturbance. The major pathological basis of PD is the death of dopaminergic neurons in the substantia nigra pars compacta (SNc) and the degeneration of their nerve terminals in striatum . It has been proposed that clinical signs of PD appear at the point when dopaminergic neuronal cell loss exceeds a critical threshold: 70 – 80% of striatal nerve terminals and 50 – 60% of the SNc perikaryons [2, 3]. As a pharmaceutical treatment, ʟ-3,4-dihydroxyphenylalanine (ʟ-dopa), supplying the precursor of dopamine (DA), is the most commonly applied and alleviates major symptom of PD. For over 40 years, treatment with ʟ-dopa combined with an inhibitor for peripheral aromatic ʟ-amino acid decarboxylase (AADC) such as carbidopa had been established as a gold standard for PD treatment [4, 5]. However, long-term treatment with ʟ-dopa is often complicated by the development of adverse effects such as drug-induced dyskinesia . There have been additional anti-parkinsonian drugs, such as dopamine agonists mostly targeted on D2 class receptor, but their pharmaceutical potencies are not drastically better than that of ʟ-dopa. It is essential to develop novel drugs which can support therapeutic effects of ʟ-dopa with delaying expression of its side effects, or even solely effective against PD symptoms.
Serotonergic neurons play an important role in modulating extrapyramidal motor disorders such as PD and drug-induced parkinsonism [7, 8]. Some studies showed administration of agonists for 1A subtype of serotonin/5-hydroxytriptamine receptor (5-HT1AR, e.g., 8-hydroxy-2-(di-n-propylamino)tertraline and tandospirone) significantly improved various types of extrapyramidal symptoms including antipsychotic-induced bradykinesia and catalepsy, and neurotoxin-induced bradykinesia [9–11]. Therefore, the central serotonergic system is thought to be one of a favorable drug target for the treatment of PD. It is a well-known fact that serotonergic as well as noradrenergic system is a major target of antidepressants such as selective serotonin-reuptake inhibitor (SSRI) fluoxetine and fluvoxamine. Recently, a novel antidepressant mirtazapine has been developed and is now approved in many countries for clinical treatment of major depression . Mirtazapine is categorized into a noradrenergic and specific serotonergic antidepressant (NaSSA), showing multiple pharmacological actions such as inhibiting presynaptic α2 noradrenaline receptor (NAR) and selectively activating 5-HT1AR [13, 14]. Mirtazapine has higher antidepressant effects than placebo or trazodone, which is equivalent to the effect of tricyclic antidepressant (TCA) such as clomipramine and amitriptyline [15–17]. Compared to SSRI, mirtazapine showed an earlier onset of antidepressant effects . Further, the side effects of mirtazapine are reported to be lower than those of SSRI or TCA .
In 2004, Nakayama et al. reported mirtazapine increased DA release in the medial prefrontal cortex (mPFC) of rats with activating 5-HT1AR . They reported that 8 or 16 mg/kg of mirtazapine increased DA release with dose-dependent manner, and an inhibitor of 5-HT1AR WAY100635 significantly decreased the mirtazapine-induced increase of DA release. We hypothesized mirtazapine may be effective on PD if the same mechanism as this 5-HT-dependent increase of DA release existed in the nigro-striatal dopaminergic system, too. In fact with related to PD, some studies reported the clinical efficacy of mirtazapine on Parkinsonian tremor in human [21, 22]. However, little is known about the therapeutic effect of mirtazapine for motor dysfunctions other than tremor in PD. Therefore, in this study, we examined the effect of mirtazapine in mice treated with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), one of the typical animal models of PD [23, 24].
Effect of mirtazapine on motor dysfunctions induced by MPTP
We first assessed effect of mirtazapine on motor dysfunctions induced by MPTP using two different behavioral paradigms: the beam-walking and rota-rod tests.
We chose two doses of mirtazapine (4 and 16 mg/kg) in this study based on the previous study by Nakayama et al. in 2004  in which they showed 4, 8 and 16 mg/kg of mirtazapine produced a dose-dependent increase in extracellular DA levels in mPFC of freely moving rats. Thus we examined minimal (4 mg/kg) and maximal (16 mg/kg) doses in mice.
With rota-rod test, vehicle-treated mice usually remained on the rotating rod for approximately 400–600 sec. As shown in Figure 1B, MPTP-treatment significantly decreased the latency to fall from the rod when compared to vehicle-treated mice (F(B) 4,44 = 7.341, P < 0.05, ANOVA). On the other hand, administration of 16 mg/kg of mirtazapine after MPTP significantly recovered the latency to the level of vehicle-treated group (Figure 1B; P < 0.05, ANOVA), with no effect when solely applied.
Effect of mirtazapine on the striatal DA, DOPAC, HVA and turnover rate
Effect of mirtazapine on the striatal TH, DAT and VMAT2 protein expression
Antagonism of WAY100635 on the behavioral effects of mirtazapine
Antagonism of prazosin or clonidine on the behavioral effects of mirtazapine
As we did in the previous section using WAY100635, we also examined both of the noradrenergic drugs on the basal behavioral activities of beam-walking and rota-rod tests. In beam-walking test, prazosin did not affect the periods for traversing 50 cm, although clonidine significantly increased it (Figure 5A; P < 0.01, ANOVA). In rota-rod test, both prazosin and clonidine significantly shortened the latency to fall from the rotating rod (Figure 5B; P < 0.01, ANOVA), suggesting some of the effects we have observed contain basal disturbance of these drugs on autonomic system.
Antagonism of WAY100635, prazosin and clonidine on the biochemical effects of mirtazapine
The effect of WAY100635, prazosin or clonidine on the striatal dopamine, DOPAC and HVA
19.49 ± 0.75**
1.62 ± 0.12**
1.03 ± 0.04**
0.14 ± 0.01
WAY100635 (0.05 mg/kg)
18.22 ± 1.21**
1.73 ± 0.09**
0.91 ± 0.04**
0.15 ± 0.01
prazosin (0.03 mg/kg)
20.27 ± 2.33**
1.51 ± 0.14**
0.79 ± 0.09**
0.12 ± 0.01 #
clonidine (0.15 mg/kg)
22.76 ± 1.88**
1.47 ± 0.07**
0.84 ± 0.05**
0.10 ± 0.01 ##
3.38 ± 0.35
0.51 ± 0.05
0.44 ± 0.04
0.28 ± 0.01 ##
MPTP + mirtazapine (16 mg/kg)
1.90 ± 1.21
0.38 ± 0.08
0.29 ± 0.06
0.78 ± 0.25*
MPTP + mirtazapine (16 mg/kg) + WAY100635 (0.05 mg/kg)
2.25 ± 0.47
0.40 ± 0.10
0.32 ± 0.08
0.33 ± 0.05†
MPTP + mirtazapine (16 mg/kg) + prazosin (0.03 mg/kg)
3.49 ± 0.48
0.56 ± 0.04
0.37 ± 0.01
0.28 ± 0.03†
MPTP + mirtazapine (16 mg/kg) + clonidine (0.15 mg/kg)
2.90 ± 0.68
0.58 ± 0.68
0.45 ± 0.07
0.31 ± 0.04†
RT-PCR detection of mRNA for the isoforms of noradrenaline and serotonin receptors
In the present study, we found that treatment with mirtazapine in mice significantly improved MPTP-induced motor dysfunction. To our knowledge, this is the first report showing the therapeutic potency of an antidepressant mirtazapine against MPTP neurotoxicity in mice. Because MPTP mice are one of the most popular models for screening anti-PD agents [23–26, 30], our results suggest possible use of mirtazapine as a PD therapeutics in clinical patients.
Our results of HPLC in Figure 2 and Table 1 showed MPTP increased DA turnover in striatum, and mirtazapine further elevated it. Similar results were reported previously by zonisamide, an anti-convulsant drug also effective on PD . Increased DA turnover with MPTP treatment is thought as a compensatory effect exerted by the remained DA neurons under the neurotoxic condition [26, 31], although significant behavioral deficits (Figure 1) suggested the compensatory effect was insufficient to keep the normal motor coordination. Further elevation of DA turnover with mirtazapine after MPTP treatment observed in this study led us to speculate mirtazapine facilitate utilization of DA, probably by increasing DA release, reuptake, degradation and/or recycling in the DA-depleted condition. Supporting this idea, in fact, reduced protein expression of DAT by MPTP was partially recovered, and that of VMAT2 was almost completely recovered to the normal level by mirtazapine (Figure 3B and C). The increase of these transporter proteins would reflect the increased DA release from the dopaminergic nerve terminals in striatum by mirtazapine [32, 33]. In contrast, reduction of TH expression with MPTP was not rescued by mirtazapine (Figure 3A), suggesting it did not affect on the neurodegenerative process of MPTP.
As mentioned in Introduction, mirtazapine is categorized into NaSSA, inhibiting pre-synaptic α2-NAR specifically. Mirtazapine also inhibits 5-HT2 and 5-HT3 receptors which in turn selectively activate 5-HT1R. It enhances, therefore, the release of noradrenaline and 5-HT1AR-mediated serotonergic transmission . Based on these pharmacological properties of mirtazapine and from our results of the experiments using NAR- and 5-HTR-related reagents, we illustrated a hypothetical mechanism of mirtazapine action on PD-related nigro-striatal dopaminergic system with serotonergic and noradrenergic systems (Figure 8). WAY100635, a selective inhibitor for 5-HT1AR, clearly cancelled the therapeutic effects of mirtazapine on MPTP-induced neurotoxicity without affecting the basal behavioral or the biochemical parameters (Figures 4 and 5, Table 1), strongly suggest the involvement of this receptor for the effects of mirtazapine. From the dorsal raphe nuclei, 5-HT neurons innervate directly to the nigral DA neurons to inhibit the firing of them with 5-HT2AR-dependent manner [28, 36]. Inhibition of this 5-HT2AR by mirtazapine results in increase of DA release. Further, the recurrent innervation of 5-HT neurons via 5-HT1AR in raphe negatively controls cell firing and release of 5-HT . Thus, activation of 5-HT1AR by mirtazapine can reduce 5-HT release, and it also results in the increased DA release. In fact, our RT-PCR results showed expression of both 5-HT2AR mRNA in SNc and 5-HT1AR in raphe (Figure 7). Recently, it has been reported that 5-HT2AR antagonists M100907 improved motor impairments in the MPTP-induced mouse model of PD . Other studies also revealed that stimulation of 5-HT1AR recovered the motor disorders caused by lesions of DA neurons or DA depletion [39–42]. Thus, both 5-HT1AR and 5-HT2AR are attractive targets as novel PD therapeutics. α2-NAR is another inhibitory target of mirtazapine. In fact, clonidine, a selective agonist for this receptor reduced the effects of mirtazapine, although it also affected basal activity of mice and striatal DA turnover (Figures 6 and 5, Table 1), probably of its inhibitory effect on peripheral sympathetic system. Noradrenaline inhibits the neurotransmitter release via presynaptic α2-NAR, and mirtazapine increases neurotransmitter release by inhibiting this receptor [13, 14]. Although precise mechanism is still unknown, we speculate this receptor could also function as presynaptic hetero receptor on DA neuron to regulate DA release negatively, the same as presynaptic autoreceptor on noradrenergic nerve terminal (Figure 8). Actually we detected α2A and α2B mRNA isoforms both in striatum and SNc (Figure 7). Prazosin, an antagonist for α1-NAR, also showed similar effects as clonidine. We suppose noradrenergic input on DA would activate DA neuron via α1-NAR in SNc as illustrated in Figure 8, since similar stimulatory mechanism was reported in 5-HT and other neurons . However, we could not clearly discriminate peripheral and central effects of the noradrenergic drugs in this study. It will be difficult to use clonidine (0.15 mg/kg) and prazosin (0.03 mg/kg) to address the mechanism for mirtazapine effect in this mouse model with a systemic administration. Precise mechanism of the effect of mirtazapine through noradrenergic system should be examined, with applying more specific inhibitors directly into specific brain regions, for example.
It is a well known fact that long-term treatment of ʟ-dopa in PD patients causes various adverse side effects such as wearing-off, dyskinesia, psychiatric symptoms, and so on [44, 45]. A recent study has demonstrated that treatment with a SSRI fluoxetine significantly suppressed ʟ-dopa-induced rotational behavior in 6-hydroxydopamine (6-OHDA)-treated rats with 5-HT1AR-dependent manner . Furthermore, a selective α2-NAR antagonist fipamezole reduced ʟ-dopa-induced dyskinesias in MPTP-treated monkeys . These observations suggest that NaSSA mirtazapine could be a possible novel therapeutic drug for PD, particularly in regard to avoiding the adverse side effects of ʟ-dopa. Depression in PD patients is the most common psychiatric disturbance , and SSRIs are now often used for the treatment . Recently, NaSSA is also used and shown to be effective in the treatment of depression in PD patients as well as SSRI [48, 50]. However, the effect of NaSSA on motor dysfunction in PD patients is still unknown. Together with these reports and our results in this study, it is highly expected that mirtazapine has dual therapeutic effects both on depression and PD in humans. Our study here and further detailed examinations will open the next door of clinical trial to examine mirtazapine on PD.
Our present study provides the first evidence that mirtazapine has a therapeutic potency against MPTP neurotoxicity in mice. Because PD patients sometimes show depression together, it is highly expected that mirtazapine has dual therapeutic effects both on depression and PD in humans.
Male C57BL/6 mice (Nihon SLC Co., Shizuoka, Japan), 8 weeks of age, were used in this study. The animals were housed in a controlled environment (23 ± 1°C, 50 ± 5% humidity) and were allowed food and tap water ad libitum. The room lights were on between 8:00 and 20:00. All handlings and procedures of animal experiments were performed in accordance with the National Institute of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978), and approved by the Committee for Animal Experiments of the University of Tokushima (#10138).
Mice were injected with 20 mg/kg of MPTP (Sigma-Aldrich, St. Louis, MO, USA) or saline intraperitoneally (i.p.) every 2 hr for a total of four injections, resulting in a cumulative dose of 80 mg/kg, as described previously . Mirtazapine (generously provided by Meiji Seika Pharma Co., Ltd., Japan) was dissolved in 0.5% carboxymethylcellulose, and was applied once a day with 4 or 16 mg/kg i.p. started from 1 hr after the final MPTP treatment for 4 days. WAY100635 (0.5 mg/kg, Sigma-Aldrich, St. Louis, MO, USA), prazosin (0.03 mg/kg, Sigma-Aldrich, St. Louis, MO, USA) and clonidine (0.15 mg/kg, Sigma-Aldrich, St. Louis, MO, USA) were dissolved in saline, and each of them was administered 1 hr before treating with mirtazapine.
Three days after MPTP or saline treatment, behavioral tests were performed 1 hr after the final treatment with mirtazapine or vehicle. For the behavioral analysis, we examined with two different experimental paradigms.
The apparatus used in this experiment was a modification of that used by Allbutt and Henderson . Before MPTP treatment, mice were trained to transverse a wooden round beam with 12 mm diameter, 80 cm length, suspended 55 cm above the floor, in two consecutive trains with 3 hr intervals each day for 3 days. Three days post-MPTP or saline treatment, mice were subjected to trials on the beam with 8 mm rather than 12 mm diameter during which they were video-recorded. The time to reach a distance of 50 cm was measured.
Rota rod test
The Rota rod treadmill (Constant Speed Model, Ugo Basile, Varese, Italy) consists of a plastic rod, 6 cm in diameter and 36 cm long, with a non-slippery surface 20 cm above the base (trip plate). This rod is divided into five equal sections by six discs (25 cm in diameter), which enables five mice to walk on the rod at the same time. In the present study, rotor mode with a constant speed was used. All the mice used were subjected to one training session a day for 3 consecutive days before MPTP treatment with 20 rpm for 10 min. At the trial session performed 3 days after MPTP treatment, the latency to fall of the animals from the rotating rod (32 rpm for 10 min) after they were placed on it was recorded as the performance time, as described previously .
Quantification of DA and its metabolites
The mice were killed by cervical dislocation 3 days after the final treatment with saline or MPTP. The striatum were rapidly dissected out on ice and sonicated in ice-cold 50 nM perchloric acid containing 1 μg/ml isoproterenol as an internal standard. DA, DOPAC and HVA were quantified by HPLC with an electrochemical detector (ECD) (Eicom, Kyoto, Japan). Concentrations of dopamine and its metabolites were expressed as μg/g tissue weight, as described previously [53, 54].
Western blot analysis
The striatal tissues were homogenized in (50 mM Tris–HCl, pH 7.5, 0.5 M NaCl, 0.5% Triton X-100, 10 mM EDTA, 4 mM EGTA, 1 mM Na3VO4, 30 mM Na4P2O7, 50 mM NaF, 0.1 mM leupeptin, 0.075 mM pepstatin A, 0.05 mg/ml trypsin inhibitor, 1 mM phenylmethanesulfonyl fluoride, 100 nM calyculin A, and 1 mM dithiothreitol) using a microtube homogenizer. Insoluble materials were removed by centrifugation at 15,000 rpm (CT15RE, HITACHI, Ibaragi, Japan) for 10 min. The supernatants were mixed with Laemmli's sample buffer (final concentrations, 63 mM Tris–HCl, pH 6.8, 2% SDS, 5% β-mercaptoethanol, 2.5% glycerol, and 0.0083% bromphenol blue) and boiled for 5 min. Protein concentrations of the sample were determined using the Bradford protein assay. Ten micrograms of protein from each sample were separated on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel using constant current. Separated proteins were transferred to polyvinylidene difluoride (PVDF) membranes at 75 V for 1.5 hr using a Trans Blot Cell (Bio-Rad, CA, USA). The membranes were incubated for 1 h at room temperature with Tris-buffered saline containing 0.1% Tween 20 (TBST) and 0.5% skim milk, followed by overnight incubation at 4°C with desired primary antibodies. The anti-TH antibody (1:1000, Chemicon International, Inc., Temecula, CA, USA) and anti-DAT antibody (1:1000, Chemicon International Inc., Temecula, CA, USA) as a marker of dopaminergic neurons were used. The anti-VMAT2 antibody (1:500, Santa Cruz Biotechnology, CA, USA) as a maker of presynaptic components was used. Membranes were washed six times for 5 min each at room temperature and incubated with horseradish peroxidase-conjugated secondary antibody in TBST for 1 hr. Immunoreactive bands were visualized by enhanced chemiluminescent autoradiography (ECL Kit, GE healthcare, Buckinghamshire, UK), according to manufacturer’s instructions. Actin antibody (Sigma, Saint Louis, MO, USA) was used as a house keeping protein to confirm that equal amounts of protein were loaded in each line. Optical densities were determined using a computerized image analysis system (Dolphin-DOC, Kurabo, Osaka, Japan), as described previously [25, 55].
RNA isolation and RT-PCR
Total RNA from striatum, SNc or raphe was purified using RNAiso plus (Takara Bio, Tokyo, Japan) according to manufacturer’s protocol. Reverse transcription from RNA to cDNA was performed using M-MLV reverse transcriptase and other supplements (Promega, Madison, WI, USA). Polymerase chain reaction (PCR) with GoTaq Green (Promega, Madison, WI, USA) was performed with using glyceraldehyde phosphate dehydrogenase (GAPDH) as an internal control. The following primers for mouse noradrenaline and 5-HT receptors with GAPDH were used (name, accession number, forward (F) or reverse (R) primer sequence, product length):
α1A, NM_07417, (F) CGACAAGTCAGACTCAGAGCAAGTGA,
(R) TGTAGCCCAGGGCATGCTTGGAAGAC, 403 bp;
α1B, NM_007416, (F) TTTCATGAGGACACCCTCAGCAGTACC,
(R) CTGCCACTGTCATCCAGAGAGTCC, 451 bp;
α1D, NM_013460, (F) CGCCAAAGGAAATCCAGGGACAC,
(R): CAGAGCGGAACTTATGGGACAGG, 616 bp;
α2A, NM_013461, (F) TTCTTTTTCACCTACACGCTCA,
(R) TGTAGATAACAGGGTTCAGCGA, 121 bp;
α2B, NM_009633, (F) ACCTTCCCTTGCTGACTGTACT,
(R) TGGGAGGGAGGTATTCTAATCA, 111 bp;
5HT1A, NM_008303, (F) TGCTCATGCTGGTCCTCTAT,
(R) TCTCAGCACTGCGCCTGC, 179 bp;
5HT2A, NM_172812, (F) AAGCCTCGAACTGGACAATTGATG,
(R) TGATTTTCAGGAAGGCTTTGGTT, 477 bp;
5HT2B, NM_008311, (F) CTCGGGGGTGAATCCTCTGA,
(R) CCTGCTCATCACCTCTCTCAG, 366 bp;
5HT2C, NM_008312, (F) CAGATCAGAAGCCACGTCGA,
(R) GGCTTATAATCGCAGCGCAA, 318 bp;
5HT3, NM_013561, (F) GCCACCCAGGCCCGAGATAC,
(R) GCTCCCACTCGCCCTGATTT, 564 bp;
GAPDH, M32599, (F) GCCAAAGGTCATCCATGACAACTTTG,
(R) CATTGGGGGTAGGAACACGGAAGGC, 237 bp;
All of the PCR reactions were started with heating 95°C for 2 min, followed by the repeated cycle of 95°C for 30 sec, 57 - 61°C for 45 sec and 72°C for 1 min, with additional 72°C for 10 min. After repeated thermal reactions for 30 cycles, the PCR products were separated by gel electrophoresis with 1% agarose containing 5 μg/mL of ethidium bromide.
All values were expressed as the means ± SEM and statistical significance was evaluated by one-way analysis of variance (ANOVA) followed by Scheffe test, Student-Newman-Keuls test or Student’s t-test (Stat View version 5.0, SAS Institute Inc., USA). Statistical differences were considered with significance at P < 0.05.
5-hydroxytriptamine 1A receptor
ʟ-amino acid decarboxylase
Glyceraldehyde phosphate dehydrogenase
High performance liquid chromatography
Medial prefrontal cortex
Noradrenergic and specific serotonergic antidepressant
Polymerase chain reaction
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
Substantia nigra pars compacta
Tris-buffered saline containing 0.1% Tween 20
Vesicular monoamine transporter 2.
The authors thank Mr. Gary W. Guzik for English proofreading. This study was supported by an ordinary grant in The University of Tokushima for research and education in each laboratory.
- Samii A, Nutt JG, Ransom B: Parkinson's disease. Lancet. 2004, 363: 1783-1793.View ArticlePubMedGoogle Scholar
- Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973, 20: 415-455.View ArticlePubMedGoogle Scholar
- Agid Y: Parkinson’s disease: pathophysiology. Lancet. 1991, 337: 1321-1324.View ArticlePubMedGoogle Scholar
- Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE: Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. J Neurol. 2002, 58: 11-17.View ArticleGoogle Scholar
- Jain L, Benko R, Safranek S: Clinical inquiry. Which drugs work best for early Parkinson's disease?. J Fam Pract. 2012, 61: 106-108.PubMedGoogle Scholar
- Rascol O, Fabre N: Dyskinesia: ʟ-dopa-induced and tardive dyskinesia. Clin Neuropharmacol. 2001, 24: 313-323.View ArticlePubMedGoogle Scholar
- Mathur BN, Lovinger DM: Serotonergic action on dorsal striatal function. Parkinsonism Relat Disord. 2012, 18 (Suppl 1): 129-131.View ArticleGoogle Scholar
- Cheshire PA, Williams DR: Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. J Clin Neurosci. 2012, 19: 343-348.View ArticlePubMedGoogle Scholar
- Prinssen EP, Colpaert FC, Koek W: 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol. 2002, 453: 217-221.View ArticlePubMedGoogle Scholar
- Neal-Beliveau BS, Joyce JN, Lucki I: Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther. 2003, 265: 207-217.Google Scholar
- Ohno Y: Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther. 2011, 17: 58-65.View ArticlePubMedGoogle Scholar
- Holm KJ, Markham A: Mirtazapine: a review of its use in major depression. Drugs. 1999, 57: 607-631.View ArticlePubMedGoogle Scholar
- De Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1996, 10 (Suppl 4): 19-23.Google Scholar
- De Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996, 57 (Suppl 4): 19-25.PubMedGoogle Scholar
- Bremner JD: A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry. 1995, 56: 519-525.PubMedGoogle Scholar
- van Moffaert M, de Wilde J, Vereecken A, Dierick M, Evrard JL, Wilmotte J, Mendlewicz J: Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol. 1995, 10: 3-9.View ArticlePubMedGoogle Scholar
- Fawcett J, Barkin RL: Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998, 51: 267-285.View ArticlePubMedGoogle Scholar
- Amini H, Aghayan S, Jalili SA, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M: Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. J Clin Pharm Ther. 2005, 30: 133-138.View ArticlePubMedGoogle Scholar
- Høyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C: A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand. 1996, 93: 184-190.View ArticlePubMedGoogle Scholar
- Nakayama K, Sakurai T, Katsu H: Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bull. 2004, 63: 237-241.View ArticlePubMedGoogle Scholar
- Gordon PH, Pullman SL, Louis ED, Frucht SJ, Fahn S: Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord. 2002, 9: 125-126.View ArticlePubMedGoogle Scholar
- Fox SH: Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs. 2013, 73: 1405-1415.View ArticlePubMedGoogle Scholar
- Kasahara J, Choudhury ME, Yokoyama H, Kadoguchi N, Nomoto M: Neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced animal models for Parkinson's disease. Animal Models for The Study of Human Disease. Edited by: Conn PM. 2013, London: Academic Press, 633-650.View ArticleGoogle Scholar
- Yokoyama H, Kuroiwa H, Kasahara J, Araki T: Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced mouse model of Parkinson's disease. Acta Neurobiol Exp. 2011, 71: 269-280.Google Scholar
- Yokoyama H, Yano R, Kuroiwa H, Tsukada T, Uchida H, Kato H, Kasahara J, Araki T: Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice. Metab Brain Dis. 2010, 25: 135-143.View ArticlePubMedGoogle Scholar
- Yabe H, Choudhury ME, Kubo M, Nishikawa N, Nagai M, Nomoto M: Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J Pharmacol Sci. 2009, 110: 64-68.View ArticlePubMedGoogle Scholar
- Grenhoff J, Svensson TH: Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur J Pharmacol. 1993, 233: 79-84.View ArticlePubMedGoogle Scholar
- Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996, 153: 466-476.View ArticlePubMedGoogle Scholar
- Blier P: Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci. 2001, 26 (Suppl): 3-10.Google Scholar
- Blandini F, Armentero MT: Animal models of Parkinson's disease. FEBS J. 2012, 279: 1156-1166.View ArticlePubMedGoogle Scholar
- Rose S, Nomoto M, Kelly E, Kilpatrick G, Jenner P, Marsden CD: Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci Lett. 1989, 101: 305-310.View ArticlePubMedGoogle Scholar
- Gainetdinov RR, Caron MG: Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol. 2003, 43: 261-284.View ArticlePubMedGoogle Scholar
- Leviel V: Dopamine release mediated by the dopamine transporter, facts and consequences. J Neurochem. 2011, 118: 475-489.View ArticlePubMedGoogle Scholar
- Dazzi L, Spiga F, Pira L, Ladu S, Vacca G, Rivano A, Jentsch JD, Biggio G: Inhibition of stress- or anxiogenic-drug-induced increases in dopamine release in the rat prefrontal cortex by long-term treatment with antidepressant drugs. J Neurochem. 2001, 76: 1212-1220.View ArticlePubMedGoogle Scholar
- Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001, 7: 249-264.View ArticlePubMedGoogle Scholar
- Di Giovanni G, Esposito E, Di Matteo V: Role of serotonin in central dopamine dysfunction. CNS Neurosci Ther. 2010, 16: 179-194.View ArticlePubMedGoogle Scholar
- Sharp T, Boothman L, Raley J, Quérée P: Important messages in the 'post': recent discoveries in 5-HT neurone feedback control. Trends Pharmacol Sci. 2007, 28: 629-636.View ArticlePubMedGoogle Scholar
- Ferguson MC, Nayyar T, Deutch AY, Ansah TA: 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Neuropharmacology. 2010, 59: 31-36.PubMed CentralView ArticlePubMedGoogle Scholar
- Mignon L, Wolf WA: Postsynaptic 5-HT1A receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology. 2002, 163: 85-94.View ArticlePubMedGoogle Scholar
- Ishibashi T, Ohno Y: Antiparkinsonian actions of a selective 5-HT1A agonist, tandospirone, in rats. Biog Amines. 2004, 8: 329-338.View ArticleGoogle Scholar
- Dupre KB, Eskow KL, Barnum CJ, Bishop C: Striatal 5-HT1A receptor stimulation reduces D1 receptor-induce dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology. 2008, 55: 1321-1328.PubMed CentralView ArticlePubMedGoogle Scholar
- Shimizu S, Tatara A, Imaki J, Ohno Y: Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog Neuro-Psychopharmacol Biol Psychiat. 2010, 34: 877-881.View ArticleGoogle Scholar
- El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P: Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther. 2010, 16: e1-17.PubMed CentralView ArticlePubMedGoogle Scholar
- Ogawa N, Asanuma M, Miyazaki I, Diaz-Corrales F, Miyoshi K: ʟ-DOPA treatment from the viewpoint of neuroprotection: Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson’s disease. J Neurol. 2005, 252 (Suppl 4): iv23-iv31.PubMedGoogle Scholar
- Ahlskog JE, Munenter MD: Frequency of levodoparelated dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001, 16: 448-458.View ArticlePubMedGoogle Scholar
- Inden M, Abe M, Minamino H, Takata K, Yoshimoto K, Tooyama I, Kitamura Y: Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on ʟ-DOPA-induced rotational behavior in a hemiparkinsonian rat model. J Pharmacol Sci. 2012, 119: 10-19.View ArticlePubMedGoogle Scholar
- Johnston TH, Fox SH, Piggott MJ, Savola JM, Brotchie JM: The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Mov Disord. 2012, 25: 2084-2093.View ArticleGoogle Scholar
- Costa FH, Rosso AL, Maultasch H, Nicaretta DH, Vincent MB: Depression in Parkinson's disease: diagnosis and treatment. Arq Neuropsiquiatr. 2012, 70: 617-620.View ArticlePubMedGoogle Scholar
- Perez-Lloret S, Rascol O: Parkinson disease: Serotonin reuptake inhibitors for depression in PD. Nat Rev Neurol. 2012, 8: 365-366.View ArticlePubMedGoogle Scholar
- Goodnick PJ, Hernandez M: Treatment of depression in comorbid medical illness. Expert Opin Pharmacother. 2000, 1: 1367-1384.View ArticlePubMedGoogle Scholar
- Kadoguchi N, Umeda M, Kato H, Araki T: Proteasome Inhibitor Does Not Enhance MPTP Neurotoxicity in Mice. Cell Mol Neurobiol. 2008, 28: 971-979.View ArticlePubMedGoogle Scholar
- Allbutt HN, Henderson JM: Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease. J Neurosci Methods. 2007, 159: 195-202.View ArticlePubMedGoogle Scholar
- Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y: Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci. 2001, 12: 231-238.View ArticlePubMedGoogle Scholar
- Kurosaki R, Muramatsu Y, Kato H, Araki T: Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease. Pharmacol Biochem Behav. 2004, 78: 143-153.View ArticlePubMedGoogle Scholar
- Takagi S, Hayakawa N, Kimoto H, Kato H, Araki T: Damage of oligodendrocytes in the striatum after MPTP neurotoxicity in mice. J Neural Transm. 2007, 114: 1553-1557.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.